Literature DB >> 20083117

Calcium sensitivity, force frequency relationship and cardiac troponin I: critical role of PKA and PKC phosphorylation sites.

Genaro A Ramirez-Correa1, Sonia Cortassa, Brian Stanley, Wei Dong Gao, Anne M Murphy.   

Abstract

Transgenic models with pseudo phosphorylation mutants of troponin I, PKA sites at Ser 22 and 23 (cTnIDD(22,23) mice) or PKC sites at Ser 42 and 44 (cTnIAD(22,23)DD(42,44)) displayed differential force-frequency relationships and afterload relaxation delay in vivo. We hypothesized that cTnI PKA and PKC phosphomimics impact cardiac muscle rate-related developed twitch force and relaxation kinetics in opposite directions. cTnIDD(22,23) transgenic mice produce a force frequency relationship (FFR) equivalent to control NTG albeit at lower peak [Ca(2+)](i), while cTnIAD(22,23)DD(42,44) TG mice had a flat FFR with normal peak systolic [Ca(2+)](i), thus suggestive of diminished responsiveness to [Ca(2+)](i) at higher frequencies. Force-[Ca(2+)](i) hysteresis analysis revealed that cTnIDD(22,23) mice have a combined enhanced myofilament calcium peak response with an enhanced slope of force development and decline per unit of [Ca(2+)](i), whereas cTnIAD(22,23)DD(42,44) transgenic mice showed the opposite. The computational ECME model predicts that the TG lines may be distinct from each other due to different rate constants for association/dissociation of Ca(2+) at the regulatory site of cTnC. Our data indicate that cTnI phosphorylation at PKA sites plays a critical role in the FFR by increasing relative myofilament responsiveness, and results in a distinctive transition between activation and relaxation, as displayed by force-[Ca(2+)](i) hysteresis loops. These findings may have important implications for understanding the specific contribution of cTnI to beta-adrenergic inotropy and lusitropy and to adverse contractile effects of PKC activation, which is relevant during heart failure development. Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20083117      PMCID: PMC2854165          DOI: 10.1016/j.yjmcc.2010.01.004

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  53 in total

Review 1.  Regulation of contraction in striated muscle.

Authors:  A M Gordon; E Homsher; M Regnier
Journal:  Physiol Rev       Date:  2000-04       Impact factor: 37.312

2.  Myofilament properties comprise the rate-limiting step for cardiac relaxation at body temperature in the rat.

Authors:  Paul M L Janssen; Linda B Stull; Eduardo Marbán
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-02       Impact factor: 4.733

3.  Power output is increased after phosphorylation of myofibrillar proteins in rat skinned cardiac myocytes.

Authors:  T J Herron; F S Korte; K S McDonald
Journal:  Circ Res       Date:  2001-12-07       Impact factor: 17.367

4.  Frequency-dependent changes in calcium cycling and contractile activation in SERCA2a transgenic mice.

Authors:  K Hashimoto; N G Perez; H Kusuoka; D L Baker; M Periasamy; E Marbán
Journal:  Basic Res Cardiol       Date:  2000-04       Impact factor: 17.165

5.  Positive force- and [Ca2+]i-frequency relationships in rat ventricular trabeculae at physiological frequencies.

Authors:  J Layland; J C Kentish
Journal:  Am J Physiol       Date:  1999-01

6.  Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a.

Authors:  S E Harding; U Schmidt; T Matsui; Z B Kang; G W Dec; J K Gwathmey; A Rosenzweig; R J Hajjar
Journal:  Circulation       Date:  1999-12-07       Impact factor: 29.690

7.  Phosphorylation of troponin I by protein kinase A accelerates relaxation and crossbridge cycle kinetics in mouse ventricular muscle.

Authors:  J C Kentish; D T McCloskey; J Layland; S Palmer; J M Leiden; A F Martin; R J Solaro
Journal:  Circ Res       Date:  2001-05-25       Impact factor: 17.367

8.  Levosimendan improves diastolic and systolic function in failing human myocardium.

Authors:  P M Janssen; N Datz; O Zeitz; G Hasenfuss
Journal:  Eur J Pharmacol       Date:  2000-09-15       Impact factor: 4.432

9.  Targeting phospholamban by gene transfer in human heart failure.

Authors:  Federica del Monte; Sian E Harding; G William Dec; Judith K Gwathmey; Roger J Hajjar
Journal:  Circulation       Date:  2002-02-26       Impact factor: 29.690

10.  Phosphorylation of troponin I controls cardiac twitch dynamics: evidence from phosphorylation site mutants expressed on a troponin I-null background in mice.

Authors:  YeQing Pi; Kara R Kemnitz; Dahua Zhang; Evangelia G Kranias; Jeffery W Walker
Journal:  Circ Res       Date:  2002-04-05       Impact factor: 17.367

View more
  23 in total

1.  β-adrenergic effects on cardiac myofilaments and contraction in an integrated rabbit ventricular myocyte model.

Authors:  Jorge A Negroni; Stefano Morotti; Elena C Lascano; Aldrin V Gomes; Eleonora Grandi; José L Puglisi; Donald M Bers
Journal:  J Mol Cell Cardiol       Date:  2015-02-25       Impact factor: 5.000

2.  Combined troponin I Ser-150 and Ser-23/24 phosphorylation sustains thin filament Ca(2+) sensitivity and accelerates deactivation in an acidic environment.

Authors:  Benjamin R Nixon; Shane D Walton; Bo Zhang; Elizabeth A Brundage; Sean C Little; Mark T Ziolo; Jonathan P Davis; Brandon J Biesiadecki
Journal:  J Mol Cell Cardiol       Date:  2014-03-19       Impact factor: 5.000

3.  CaMKII-dependent myofilament Ca2+ desensitization contributes to the frequency-dependent acceleration of relaxation.

Authors:  Arnaud Guilbert; Hyun Joung Lim; Jun Cheng; Yanggan Wang
Journal:  Cell Calcium       Date:  2015-08-07       Impact factor: 6.817

Review 4.  TNFα in myocardial ischemia/reperfusion, remodeling and heart failure.

Authors:  Petra Kleinbongard; Rainer Schulz; Gerd Heusch
Journal:  Heart Fail Rev       Date:  2011-01       Impact factor: 4.214

5.  Multiple reaction monitoring to identify site-specific troponin I phosphorylated residues in the failing human heart.

Authors:  Pingbo Zhang; Jonathan A Kirk; Weihua Ji; Cristobal G dos Remedios; David A Kass; Jennifer E Van Eyk; Anne M Murphy
Journal:  Circulation       Date:  2012-09-12       Impact factor: 29.690

6.  Reactivation of fetal splicing programs in diabetic hearts is mediated by protein kinase C signaling.

Authors:  Sunil K Verma; Vaibhav Deshmukh; Patrick Liu; Curtis A Nutter; Rosario Espejo; Ming-Lung Hung; Guey-Shin Wang; Gene W Yeo; Muge N Kuyumcu-Martinez
Journal:  J Biol Chem       Date:  2013-10-22       Impact factor: 5.157

Review 7.  Redox regulation of sodium and calcium handling.

Authors:  Stefan Wagner; Adam G Rokita; Mark E Anderson; Lars S Maier
Journal:  Antioxid Redox Signal       Date:  2012-10-03       Impact factor: 8.401

8.  Apelin and APJ orchestrate complex tissue-specific control of cardiomyocyte hypertrophy and contractility in the hypertrophy-heart failure transition.

Authors:  Victoria N Parikh; Jing Liu; Ching Shang; Christopher Woods; Alex C Chang; Mingming Zhao; David N Charo; Zachary Grunwald; Yong Huang; Kinya Seo; Philip S Tsao; Daniel Bernstein; Pilar Ruiz-Lozano; Thomas Quertermous; Euan A Ashley
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-05-18       Impact factor: 4.733

9.  Long term ablation of protein kinase A (PKA)-mediated cardiac troponin I phosphorylation leads to excitation-contraction uncoupling and diastolic dysfunction in a knock-in mouse model of hypertrophic cardiomyopathy.

Authors:  David Dweck; Marcos A Sanchez-Gonzalez; Audrey N Chang; Raul A Dulce; Crystal-Dawn Badger; Andrew P Koutnik; Edda L Ruiz; Brittany Griffin; Jingsheng Liang; Mohamed Kabbaj; Frank D Fincham; Joshua M Hare; J Michael Overton; Jose R Pinto
Journal:  J Biol Chem       Date:  2014-06-27       Impact factor: 5.157

Review 10.  The continuing evolution of cardiac troponin I biomarker analysis: from protein to proteoform.

Authors:  Daniel Soetkamp; Koen Raedschelders; Mitra Mastali; Kimia Sobhani; C Noel Bairey Merz; Jennifer Van Eyk
Journal:  Expert Rev Proteomics       Date:  2017-10-16       Impact factor: 3.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.